Amyris has executed a five year Biofene supply agreement with a global nutraceuticals company, which replaces an existing one-year purchase agreement, which was previously announced on January 4, 2016.###Under the new supply agreement, the customer has agreed to a larger Biofene purchase in 2016 with an expected rebest zinc gluconate supplementvenue contribution of approximately US$9 million and to minimum annual purchase commitments in each of the resolaray calcium citratemaining years of the agreement.###In addition, Amyris is entitled to a quarterly value-share arrangement on the sales of the customer’s product made from the purchased Biofene.###Amyris expects total revenue from the five-year agreement to be mvitamin shoppe magnesium citrateore than US$100 milmagnesium citrate in the morninglion.###The five-year term is projected to generate approximately $40 million of annual revenuemagnesium citrate 320 mg, which Amyris expects will be renewed at that level in subsequent years.